2. Immunology/Inflammation Apoptosis
  3. Interleukin Related Apoptosis
  4. Benralizumab

Benralizumab  (Synonyms: MEDI-563; BIW-8405)

目录号: HY-P9923 纯度: 99.1%
COA

摩尔计算器

Benralizumab (MEDI-563) 是一种白介素 5 受体 α (IL-5Rα) 定向的溶细胞单克隆抗体，通过增强抗体依赖性细胞介导的细胞毒性诱导嗜酸性粒细胞直接，快速和几乎完全耗尽。Benralizumab 可用于严重的嗜酸性哮喘。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Benralizumab Chemical Structure

Benralizumab Chemical Structure

CAS No. : 1044511-01-4

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
1 mg ￥8800
In-stock
5 mg   询价  
10 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Benralizumab:

Benralizumab 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma[1].

IC50 & Target[1]

IL-5Rα

 

体外研究
(In Vitro)

Benralizumab (MEDI-563) binds to recombinant human and cynomolgus monkey IL-5Rα extracellular domains with a dissociation constant of 11 and 42 pM, respectively[2].
Benralizumab (1 pM-100 nM, 48 h) inhibits IL-5–induced proliferation of CTLL-2 cells transfected with recombinant human IL-5Rαβ with an IC50 of 0.3 nM[2].
Benralizumab binds only to the constructs containing human IL-5Rα D1[2].
Benralizumab mediates ADCC (antibody-dependent cell-mediated cytotoxicity) of human eosinophils and basophils with EC50s of 0.9 pM and 0.5 pM, respectively, and mediates eosinophil apoptosis[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Benralizumab 相关抗体:

Cell Proliferation Assay[2]

Cell Line: CTLL-2 human IL-5Rαβ cells
Concentration: 1 pM-100 nM
Incubation Time: 48 h
Result: Inhibited cell proliferation with an IC50 of 0.3 nM.
体内研究
(In Vivo)

Benralizumab (MEDI-563) (0-30 mg/kg; i.v.; once every 3 weeks for 12 weeks) reduces peripheral blood and bone marrow eosinophil[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female and male cynomolgus monkeys[2]
Dosage: 0.1, 1, 10, and 30 mg/kg
Administration: Intravenous injection, once every 3 weeks for 12 weeks
Result: Blood eosinophil counts decreased close to the limit of detection after the first administration at all dose levels and remained undetectable. Eosinophil precursors in the bone marrow were reduced 80% or greater in all doses 3 days after the last administration (terminal necropsy) and remained undetectable until 18 days after the last dose in the 30 mg/kg group. The profound effect observed in the bone marrow was specific for the eosinophil lineage.
Clinical Trial
CAS 号
性状

液体

颜色

Colorless to light yellow

中文名称

贝那利珠单抗
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料

纯度: ≥99.1%

COA (150 KB)

抗体抑制剂使用指南 (1152 KB)
参考文献

Benralizumab 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Benralizumab1044511-01-4MEDI-563 BIW-8405贝那利珠单抗MEDI563MEDI 563BIW8405BIW 8405BIW-8405Interleukin RelatedApoptosisILeosinophilic asthmachronic obstructive pulmonary diseaseCOPDInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Benralizumab
目录号：
HY-P9923
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z